跳到正文
原文
Nature 健康护理主题·· 4 天前AI 评分35

数字化与传统稳定型牙垫治疗颞下颌关节紊乱症的效果对比研究方案

Effectiveness of digitally fabricated versus conventional stabilizing splints in temporomandibular disorders: a randomized controlled trial protocol

AI 导读

一项随机对照试验旨在比较数字化与传统稳定型牙垫治疗颞下颌关节紊乱症(TMJ arthralgia)的效果。研究主要评估疼痛强度变化(Characteristic Pain Intensity, CPI)等指标,计划随访3个月。次要评估包括疼痛相关残疾、开口度、咀嚼功能限制、关节弹响及口腔健康相关生活质量等。

正文

Introduction

Temporomandibular disorders (TMD) comprise a group of musculoskeletal conditions affecting the temporomandibular joints, masticatory muscles, and associated structures. They commonly present with pain, joint sounds, restricted mandibular movement, and functional limitation, which may adversely affect patients’ oral health-related quality of life (OHRQoL) [1, 2]. Among conservative treatment approaches, stabilization splints are commonly used in the management of TMD and may contribute to reductions in pain intensity and improvements in mandibular function [3, 4].

Conventional stabilization splints are typically fabricated using heat-cured polymethyl methacrylate through a multistep laboratory process involving impression making, cast articulation, and occlusal adjustment. This workflow is technique-sensitive, time-consuming, and may introduce operator- and laboratory-related variability [5].

Advances in digital dentistry have introduced computer-aided design and computer-aided manufacturing (CAD/CAM) workflows for the fabrication of stabilization splints. Additive manufacturing and milling technologies allow splints to be designed and fabricated using standardized digital workflows, with potential advantages in reproducibility, manufacturing consistency, and fabrication efficiency [5, 6]. However, whether these potential advantages translate into clinically meaningful improvements in pain, mandibular function, or patient-reported outcomes remains uncertain [7].

Although clinical studies have compared digitally fabricated and conventionally fabricated stabilization splints, the available evidence remains limited and heterogeneous with respect to fabrication techniques, study populations, treatment protocols, and outcome measures [8,9,10]. Recent systematic reviews and meta-analyses have reported generally comparable clinical outcomes between digital and conventional splints while highlighting heterogeneity among the available trials and the need for further well-designed randomized controlled studies [9, 10].

This evidence gap is particularly relevant for patients with TMJ arthralgia, for whom pain intensity represents an important clinical outcome. A standardized pain measure such as Characteristic Pain Intensity (CPI) [8, 9], derived from the Graded Chronic Pain Scale [8], provides a continuous measure that can be used to evaluate change in pain over time.

The present randomized controlled trial has therefore been designed to compare digitally fabricated and conventionally fabricated stabilization splints in adults with TMJ arthralgia diagnosed according to the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I.

Objectives of the Study

Primary objective

To compare the effectiveness of digitally fabricated and conventionally fabricated maxillary stabilization splints in reducing Characteristic Pain Intensity (CPI; 0–100) in adults with DC/TMD- Axis I, defined temporomandibular joint arthralgia by comparing the change in CPI from baseline to 3 months after intervention.

Secondary objectives

To compare the effects of digitally fabricated and conventionally fabricated maxillary stabilization splints on:

  1. 1.

    Pain-related disability using Graded Chronic pain scale, GCPS [8] disability score and disability points from baseline to 3 months.

  2. 2.

    Maximum unassisted inter-incisal mouth opening (MMO) in mm, DC/TMD Axis I [10] examination protocol from baseline to 3 months.

  3. 3.

    Jaw functional limitation using Jaw function limitation Scale [11] (JFLS-20) from baseline to 3 months.

  4. 4.

    Temporomandibular joint clicking (presence and frequency on DC/TMD Axis I clinical examination) from baseline to 3 months, analysed in participants with a click detected at baseline.

  5. 5.

    Oral health-related quality of life using Oral Health Impact profile, OHIP-14 [12] summary score from baseline to 3 months.

  6. 6.

    Splint compliance [13], expressed as mean nightly wear time over the 12-week intervention period.

    Additional objectives

  7. 7.

    Clinical efficiency of delivery: chairside time at insertion, number of post-insertion adjustment visits, and laboratory turnaround time.

  8. 8.

    Adverse events, including mucosal irritation, occlusal change, splint fracture and loss of retention.

Primary hypothesis

There will be a difference between digitally fabricated and conventionally fabricated maxillary stabilization splints in the change in Characteristic Pain Intensity from baseline to 3 months.

Secondary hypotheses

It is hypothesized that digitally fabricated and conventionally fabricated maxillary stabilization splints will differ in their effects on:

  1. 1.

    Pain-related disability, will be assessed using the GCPS disability score and disability points, from baseline to 3 months.

  2. 2.

    Maximum unassisted inter-incisal mouth opening from baseline to 3 months.

  3. 3.

    Jaw functional limitation, will be assessed using the JFLS-20 score, from baseline to 3 months.

  4. 4.

    Temporomandibular joint clicking, with the proportion of participants demonstrating resolution of clicking at 3 months among those presenting with clicking at baseline.

  5. 5.

    Oral health-related quality of life, will be assessed using the OHIP-14 summary score, from baseline to 3 months.

  6. 6.

    Splint compliance, will be xpressed as mean nightly wear time over the 12-week intervention period.

    Additional hypotheses

  7. 7.

    Digitally fabricated stabilization splints will differ from conventionally fabricated splints with respect to clinical efficiency of delivery, including chairside insertion time, number of post-insertion adjustment visits, and laboratory turnaround time.

  8. 8.

    The frequency and nature of adverse events, including mucosal irritation, occlusal changes, splint fracture, and loss of retention, will differ between the two intervention groups.

Methodology

Trial design

This study is designed as a prospective, single-center, two-arm, parallel-group randomized controlled clinical trial with a 1:1 allocation ratio. Adults aged 18–40 years with temporomandibular joint (TMJ) arthralgia diagnosed according to the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I will be screened for eligibility. Participants who meet all predefined inclusion and exclusion criteria and provide written informed consent will be enrolled in the trial.

Eligible participants will be randomly allocated in a 1:1 ratio to either the digitally fabricated Maxillary stabilization splint group or the conventionally fabricated maxillary stabilization splint group using a computer-generated randomization sequence. Each participant will receive only one assigned intervention and will remain in the allocated group throughout the study. No crossover between intervention groups will be permitted.

Participant eligibility criteria

Participants will be eligible for inclusion if they meet all of the following criteria:

Inclusion criteria

  1. 1.

    Adults aged 18–40 years.

  2. 2.

    A diagnosis of temporomandibular joint (TMJ) arthralgia established according to the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I, based on the standardized DC/TMD clinical examination and diagnostic algorithm.

  3. 3.

    A history of TMJ pain for at least 3 months before enrollment.

  4. 4.

    Ability and willingness to wear the assigned maxillary stabilization splint according to the study protocol and attend all scheduled follow-up assessments.

  5. 5.

    Provision of written informed consent before enrollment.

Exclusion criteria

Participants will be excluded if they have:

  1. 1.

    A primary diagnosis of myalgia according to the DC/TMD.

  2. 2.

    Evidence of degenerative joint disease of the TMJ, including osteoarthritis.

  3. 3.

    A history of TMJ trauma or previous TMJ surgery.

  4. 4.

    Craniofacial anomalies or structural conditions that may affect occlusion or mandibular function.

  5. 5.

    Ongoing orthodontic treatment.

  6. 6.

    Use of an occlusal splint or other intraoral appliance for TMD management within the preceding 3 months.

  7. 7.

    A systemic joint disorder that may affect the TMJ or pain-related outcomes.

  8. 8.

    Use of medications that may substantially influence pain perception or neuromuscular function and interfere with assessment of the study outcomes.

9. Pregnancy or lactation

10. Any medical, cognitive, or psychological condition that, in the investigator’s judgment, may prevent compliance with study procedures or completion of the required follow-up assessments.

Rationale for participant selection

The study population is restricted to participants with DC/TMD- Axis I defined TMJ arthralgia to establish a clinically homogeneous pain-related TMD population and to ensure that the primary outcome, change in Characteristic Pain Intensity (CPI), directly reflects the principal symptom targeted by the intervention. Participants with primary myalgia and degenerative joint disease were excluded because these represent clinically distinct TMD conditions with different clinical characteristics and treatment considerations. Maximum unassisted mouth opening will be assessed as a secondary clinical outcome rather than used as an eligibility criterion, thereby allowing inclusion of the broader population of patients meeting the DC/TMD -Axis I diagnostic criteria for TMJ arthralgia.

Sample size calculation

The sample size was calculated for the primary outcome, namely the between-group difference in change in Characteristic Pain Intensity (CPI) from baseline to 3 months. An a priori power analysis was performed using G*Power version 3.1.9.7, with F tests: ANOVA: repeated measures, within–between interaction. The calculation assumed a small effect size (Cohen’s f = 0.15), a two-sided significance level of α = 0.05, 80% power, two treatment groups, two repeated measurements (baseline and 3 months), a correlation of 0.50 between repeated measurements, and a nonsphericity correction of ε = 1.0. Under these assumptions, the required sample size was 90 participants (45 per group). Allowing for an anticipated 25% attrition, the recruitment sample was inflated according to the formula:

$${{\rm{N}}}=90/(1-0.25)=120$$

Therefore, 120 participants (60 per group) will be recruited and randomly allocated in a 1:1 ratio to the digitally fabricated or conventionally fabricated stabilization-splint groups.

Justification of effect-size assumption

The effect-size assumption was informed by preliminary pilot observations and the available clinical literature [4,5,6,13,14]. In the investigators’ pilot observations, mean Characteristic Pain Intensity (CPI) decreased from approximately 87 to 35 in the digitally fabricated splint group and from approximately 85 to 65 in the conventionally fabricated splint group, corresponding to mean reductions of approximately 52 and 20 CPI points, respectively, and an observed between-group difference in mean change of approximately 32 CPI points. However, these observations were obtained from a small exploratory pilot and were not considered sufficiently stable to provide a reliable estimate of the treatment effect for the definitive trial. Therefore, the pilot findings were used to inform the expected direction and approximate magnitude of change rather than to derive the formal effect-size assumption.

Previous randomized clinical trials [4,5,6,13] and systematic reviews [14] have demonstrated reductions in pain outcomes following stabilization-splint treatment. However, no directly transferable effect estimate was identified for the present trial because the available studies differ from the current protocol with respect to splint fabrication method, comparator, study population, pain measurement instrument, and timing of outcome assessment. In particular, no identified study directly compared digitally fabricated with conventionally fabricated stabilization splints using the Graded Chronic Pain Scale Characteristic Pain Intensity as the primary outcome and assessed the between-group difference in change from baseline to 3 months.

Accordingly, Cohen’s f = 0.15 was prespecified as a small and conservative effect size for the treatment-by-time interaction, corresponding to the primary hypothesis that the change in CPI from baseline to 3 months would differ between the digitally fabricated and conventionally fabricated stabilization-splint groups. This conservative assumption was selected rather than extrapolating the comparatively large effect observed in the exploratory pilot or adopting an effect estimate from a clinically non-equivalent study. The resulting calculation indicated that 90 evaluable participants (45 per group) would provide 80% power at a two-sided α of 0.05. Allowing for an anticipated 25% attrition rate, the recruitment target was increased to 120 participants (60 per group).

Blinding and allocation concealment

Because the two interventions involve inherently different fabrication procedures, including digital scanning versus conventional impression making, participants and the operator involved in splint fabrication cannot be considered fully blinded to treatment allocation. The trial will therefore be described as assessor-blinded, rather than single-blinded.

Randomization will be performed using a computer-generated sequence with variable block sizes prepared by an investigator who is not involved in participant recruitment, intervention delivery, or outcome assessment. Based on this sequence, sequentially numbered, opaque, sealed envelopes will be prepared by a designated dental surgery assistant (DSA) who is not involved in outcome assessment. The envelopes will be securely retained by the DSA until allocation.

Following confirmation of eligibility, informed consent, and completion of baseline outcome assessments, the DSA will open the next sequentially numbered envelope corresponding to the participant and communicate the assigned intervention to the principal investigator. The principal investigator, a prosthodontist, will serve as the single operator responsible for splint delivery and standardized clinical adjustment in both intervention groups. The DSA will subsequently facilitate the participant’s appointment for the allocated intervention.

The allocation will therefore remain concealed until eligibility, consent, and baseline assessment have been completed. The outcome assessor will be a separate blinded examiner who is not involved in participant recruitment, randomization, splint fabrication, delivery, adjustment, or treatment. The assessor will have no access to the randomization sequence, allocation records, or treatment assignment and will remain blinded throughout the follow-up assessments. Participants will be instructed not to disclose details of their splint fabrication method to the outcome assessor. (Fig. 1), (Fig. 2)

Fig. 1

Planned CONSORT-style participant flow for the assessor-blinded randomized controlled trial comparing digitally fabricated and conventionally fabricated maxillary stabilization splints.

Fig. 2

SPIRIT Schedule of enrollment, interventions and assessments.

Emergency unblinding is not routinely anticipated because the interventions are non-pharmacological stabilization splints and knowledge of treatment allocation is not expected to be required for management of an acute adverse event. If knowledge of treatment allocation becomes necessary for the clinical management of a participant, the allocation may be disclosed by the principal investigator. Any such unblinding will be documented, including the reason, date, person authorizing the disclosure, and participant affected. The occurrence of unblinding will be reported in the study records and considered in the interpretation of the affected outcome assessments.

Intervention procedures

Participants allocated to the digital group will undergo intraoral scanning followed by computer-aided design and 3D prinring of the stabilization splint. Participants allocated to the conventional group will undergo conventional impression making, cast fabrication, articulation, and heat-cured PMMA splint fabrication. The fabrication workflow will differ between groups, but the clinical design and occlusal characteristics of the final splints will be standardized.

Splint standardization

Both intervention groups will receive standardized maxillary full-coverage stabilization splints fabricated according to the same prescribed design and occlusal scheme. The splints will provide bilateral posterior centric contacts with canine-guided occlusion, with a standardized thickness of 2–3 mm. The extent of coverage, occlusal design, and clinical adjustment protocol will be standardized across both groups. Participants in both groups will receive identical instructions regarding splint use and will be instructed to wear the splint during sleep for a minimum of 8 hours per night Any adjustment, repair, or remake required during follow-up will be documented.

Digital stabilization splint fabrication

Participants allocated to the digitally fabricated stabilization splint group will undergo maxillary intraoral scanning using a Medit i700 intraoral scanner (Medit Corp., Seoul, Republic of Korea) according to the manufacturer’s recommended scanning protocol. The resulting digital maxillary arch and occlusal records will be imported into Blue Sky Bio software, version 5.1 (Blue Sky Bio, USA) for virtual splint design. The digital splint design will be standardized according to the predefined clinical parameters, including full maxillary coverage, a thickness of approximately 2–3 mm, bilateral posterior centric contacts, and canine-guided occlusion.

Digitally fabricated stabilization splints will be manufactured using an ELEGOO Mars 5 MSLA resin 3D printer (ELEGOO, China), equipped with a 6.6-inch 4 K monochrome LCD and a 405-nm COB light source. The printer has an XY resolution of 35 × 35 μm and a manufacturer-specified layer-thickness range of 0.01–0.20 mm. A layer thickness of 50 μm and a build orientation of 45° were used for fabrication. These printing parameters were selected based on the preclinical in-vitro validation phase of the present study.All splints will be printed using a standardized 50-μm layer thickness and 45° printing orientation. validated printing parameters were subsequently used for fabrication of the digitally fabricated stabilization splints in the clinical trial. Preclinical validation included were assessment of dimensional accuracy, flexural strength, and bacterial adhesion. Based on the findings of this evaluation, the 45° orientation was selected for the present clinical trial.

Following printing, all splints will undergo standardized post-processing and post-curing according to the manufacturer’s recommended protocol for the selected resin. The processed splints will then be finished, inspected, and clinically evaluated for fit and occlusal contacts before delivery. Any necessary clinical adjustments will be performed according to the standardized adjustment protocol.

Conventional stabilization splint fabrication

Participants allocated to the conventionally fabricated stabilization splint group will undergo maxillary impression making using an appropriately sized rigid stock tray and addition silicone (polyvinyl siloxane) impression material. The tray will be seated centrally with a single controlled movement and maintained without movement until polymerization is complete. The impression will then be removed, inspected for accuracy and completeness, and disinfected. Defective impressions will be repeated. The impressions will be poured with dental stone to obtain the working casts for splint fabrication.

The maxillary cast will be mounted on a Bio-Art semi-adjustable articulator (Bio-Art, Brazil) using the Centric relation records. The stabilization splint will be fabricated using SR Triplex Hot (Ivoclar, Schaan, Liechtenstein), a heat-curing Polymethylmethacrylate material indicated for the packing/condensing technique and also specified by the manufacturer for use in occlusal splints. It will be cured according to the manufacturer’s recommended processing protocol. Following polymerization, the splint will be deflasked, finished, and polished.

Occlusal adjustment

Before delivery, the splint will be evaluated on the working cast for adaptation, extension, and integrity. Intraorally, fit, retention, and stability will be assessed. Occlusal contacts will initially be evaluated using Bausch 200-μm articulating paper, followed by refinement and verification using Bausch 40-μm articulating paper. Occlusal adjustments will be performed to achieve the predefined standardized occlusal scheme, including bilateral posterior centric contacts and canine-guided occlusion.

Operator assement and standardization

Before commencement of the clinical trial, two examiners underwent training and calibration using the standardized clinical assessment procedures specified in the study protocol. Inter-examiner calibration was performed in a subset of 20 patients, who were independently assessed by both examiners using the same standardized procedures for Characteristic Pain Intensity (CPI), maximum unassisted inter-incisal mouth opening (MMO), Jaw Functional Limitation Scale–20 (JFLS-20), and temporomandibular joint (TMJ) clicking.

Following the calibration exercise, a single examiner was selected to perform all clinical outcome assessments throughout the trial to minimize inter-examiner variability. The selected examiner remained blinded to treatment allocation and used the same instruments, measurement techniques, and standardized assessment conditions at baseline and at the 3-month follow-up.

The calibration exercise demonstrated good overall consistency. The standardized assessment procedures were maintained throughout the trial to promote consistency and minimize measurement variability.

Ethics approval and consent to participate

Ethical approval was obtained from the Institutional Review Board of Shifa Tameer-e-Millat University, Islamabad (Approval No. 243-25). The study is being conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent will be obtained from all participants before enrollment. Partcipants has the right to withdraw from the trial.

Outcome assessment

Primary outcome

The primary outcome will be the change in Characteristic Pain Intensity (CPI) from baseline to 3 months after delivery of the assigned stabilization splint. CPI will be derived from the Graded Chronic Pain Scale (GCPS) and calculated as the mean of the participant’s current pain intensity, worst pain intensity, and average pain intensity, each rated on a 0–10 numerical rating scale. The mean score will be multiplied by 10 to obtain a CPI score ranging from 0 to 100, with higher scores indicating greater pain intensity.

Primary outcome measure

Mean change in CPI score from baseline to 3 months.

Time frame

Baseline (before delivery of the stabilization splint) and 3 months post-intervention.

The primary analysis will compare the change in CPI between the digitally fabricated and conventionally fabricated stabilization splint groups.

Secondary outcomes

1. Pain-related disability

Pain-related disability will be assessed using the disability component of the GCPS. The scale includes three items assessing interference with daily, social, and work-related activities. Each item is scored from 0 to 10, and the mean score will be multiplied by 10 to obtain a disability score ranging from 0 to 100, with higher scores indicating greater pain-related disability.

Outcome measure

Mean change in pain-related disability score from baseline to 3 months.

Time frame

Baseline and 3 months post-intervention.

2. Maximum unassisted mouth opening

Maximum mouth opening (MMO) will be measured as the maximum unassisted inter-incisal distance in millimeters using a calibrated digital Vernier caliper. The measurement will be recorded to the nearest 0.1 mm under standardized clinical conditions.

Outcome measure

Mean change in maximum unassisted mouth opening (mm) from baseline to 3 months.

Time frame

Baseline and 3 months post-intervention.

Importantly, MMO will be assessed as a clinical outcome and will not be used as an eligibility criterion.

3. Jaw functional limitation

Jaw functional limitation will be assessed using the Jaw Functional Limitation Scale–20 (JFLS-20). The instrument consists of 20 items assessing limitations in mastication, vertical jaw mobility, and verbal/non-verbal communication-related functions. Each item is scored from 0 to 10, with higher scores indicating greater functional limitation. The overall score will be calculated according to the recommended scoring procedure for the JFLS-20.

Outcome measure

Mean change in JFLS-20 score from baseline to 3 months.

Time frame

Baseline and 3 months post-intervention.

4. Temporomandibular joint clicking

TMJ clicking will be assessed clinically during mandibular opening and closing by the trained and calibrated outcome assessor. Clicking will be recorded when an audible or palpable click is detected during at least one of three consecutive opening–closing cycles. The finding will be recorded as a dichotomous variable (present/absent).

Outcome measure

Proportion of participants demonstrating resolution of TMJ clicking at 3 months among those presenting with clicking at baseline.

Time frame

Baseline and 3 months post-intervention.

This definition is preferable to simply comparing the proportion of patients with clicking at baseline and follow-up because your stated outcome is specifically resolution of clicking.

5. Oral health-related quality of life

Oral health-related quality of life (OHRQoL) will be assessed using the Oral Health Impact Profile-14 (OHIP-14). The instrument comprises 14 items scored on a five-point Likert scale ranging from 0 (never) to 4 (very often), with a total score ranging from 0 to 56. Higher scores indicate greater oral health-related impact and poorer OHRQoL.

Outcome measure

Mean change in OHIP-14 score from baseline to 3 months.

Time frame

Baseline and 3 months post-intervention.

Compliance with splint use

Compliance will be assessed using a standardized daily compliance diary provided to participants at the time of splint delivery. Participants will receive standardized instructions for diary completion and will record the time at which the stabilization splint is inserted at night and removed in the morning. If the splint is removed during the night, the approximate removal and reinsertion times will also be recorded.

The diary will be reviewed at each scheduled follow-up visit. Mean nightly wear time (hours/night) will be calculated from the recorded daily wear periods over the 3-month intervention period. Participants will be reminded to complete the diary regularly to minimize recall and reporting errors.

Outcome measure

Mean nightly splint wear time (hours/night) over the 3-month intervention period.

Compliance definition

Adequate compliance will be defined a priori as wearing the stabilization splint for 8 hours per night on at least 80% of recorded nights during the intervention period.

Follow up and participants retention

Participants will receive standardized instructions regarding splint use and follow-up visits at enrollment and intervention delivery. Follow-up appointments will be scheduled in advance, and participants will be contacted through their recorded contact information before the scheduled 3-month assessment. Participants who miss a scheduled visit will be contacted to facilitate rescheduling and completion of the outcome assessment. Reasons for withdrawal, loss to follow-up, or discontinuation will be documented whenever available. All efforts will be made to obtain outcome data from participants who discontinue splint use where they remain willing to participate in follow-up assessments.

Statistical analysis

Primary analysis

The primary analysis will evaluate the between-group difference in Characteristic Pain Intensity (CPI) from baseline to 3 months using a linear mixed-effects model. CPI will be treated as a continuous outcome. The model will include treatment group (digitally fabricated versus conventionally fabricated stabilization splint), time (baseline and 3 months), and the treatment-by-time interaction as fixed effects. The treatment-by-time interaction will represent the primary test of whether the change in CPI over time differs between the two intervention groups. A participant-specific random intercept will be included to account for the correlation between repeated measurements within the same participant.

The model will provide the estimated mean difference in change in CPI between groups, together with its 95% confidence interval and two-sided P value. The primary analysis will follow the intention-to-treat principle, with participants analyzed according to their randomized treatment allocation regardless of adherence, treatment modification, or discontinuation.

Baseline CPI will be included in the longitudinal model through the baseline measurement as part of the repeated outcome structure. Relevant baseline characteristics, including age and sex, will be summarized by treatment group. If clinically important baseline imbalances are identified despite randomization, prespecified clinically relevant covariates may be included in an adjusted sensitivity analysis. Covariates will not be selected solely on the basis of statistical significance in baseline comparisons.

The assumptions of the linear mixed-effects model will be assessed by examination of model residuals, including assessment of approximate normality, homoscedasticity, and influential observations. Where substantial departures from model assumptions are identified, appropriate transformation or alternative robust/sensitivity analyses will be considered.

Secondary analyses

Secondary continuous outcomes, including pain-related disability (GCPS disability score), maximum unassisted inter-incisal mouth opening (mm), JFLS-20 score, and OHIP-14 score, will be analyzed using analogous linear mixed-effects models. Each model will include treatment group, time, and treatment-by-time interaction as fixed effects and a participant-specific random intercept. The treatment-by-time interaction will be used to assess whether the trajectory of each outcome differs between treatment groups.

Results for continuous secondary outcomes will be reported as estimated between-group differences in change from baseline to 3 months with 95% confidence intervals and two-sided P values.

For temporomandibular joint clicking, the primary secondary analysis will compare the proportion of participants with resolution of clicking at 3 months among those who demonstrated clicking at baseline. Between-group differences will be evaluated using the chi-square test or Fisher’s exact test, as appropriate based on expected cell counts. Within-participant change in clicking status will be described using McNemar’s test where appropriate. The analysis of clicking will clearly distinguish participants with clicking at baseline from those without clicking at baseline.

Splint compliance will be summarized using descriptive statistics, including mean, standard deviation, median, interquartile range, and range of nightly wear time, as appropriate. Compliance will be treated primarily as an adherence measure rather than as a primary efficacy outcome. An exploratory analysis will investigate whether compliance is associated with the primary outcome. Because compliance occurs after randomization, it will not be included as a routine adjustment covariate in the primary efficacy model, since adjustment for a post-randomization variable may introduce bias. Any compliance-adjusted analysis will therefore be considered exploratory and interpreted cautiously.

Multiplicity of secondary outcomes

Because multiple secondary outcomes are being evaluated, the analyses of secondary outcomes will be considered supportive/exploratory rather than individually powered confirmatory hypotheses. The primary hypothesis will be tested at a two-sided α level of 0.05. Effect estimates and 95% confidence intervals will be emphasized for secondary outcomes, and P values will be interpreted in the context of multiple comparisons.

Missing data and participant analysis

All randomized participants will be included in the intention-to-treat analysis to the extent permitted by the available outcome data. The linear mixed-effects models use maximum-likelihood estimation and can incorporate participants with incomplete longitudinal observations under the assumption that data are missing at random (MAR), conditional on the variables included in the model.

The extent and pattern of missing data will be reported by treatment group and assessment time point. Reasons for missing outcome assessments and participant withdrawals will also be documented where available. If the amount or pattern of missing data is greater than anticipated, additional sensitivity analyses will be performed to assess the robustness of the primary findings.

Where appropriate, multiple imputation may be used as a sensitivity analysis if the assumptions and structure of the missing data permit. Results from the primary mixed-effects analysis will be compared with the sensitivity analysis to determine whether conclusions are materially affected by the approach to missing data.

Sensitivity and supplementary analyses

Sensitivity analyses will be conducted to assess the robustness of the primary findings. These may include an adjusted analysis incorporating prespecified clinically relevant baseline covariates, alternative approaches to missing data, and a per-protocol analysis restricted to participants who adequately adhered to the assigned intervention and completed the 3-month assessment.

The intention-to-treat analysis will remain the primary analysis, and the per-protocol and compliance-related analyses will be considered supplementary.

Independent-samples t-tests or non-parametric tests of change scores will not be used as routine primary or secondary analyses, because the prespecified longitudinal mixed-effects framework is more appropriate for the repeated-measures study design and can accommodate incomplete follow-up data. Such analyses may be reported only as supplementary analyses if required for comparison with previous literature.

Interim analysis and stopping rules

No formal interim analysis of treatment efficacy is planned. The primary analysis will be performed after completion of recruitment and the prespecified 3-month follow-up period. No formal statistical stopping rule for efficacy or futility will be applied. The study may nevertheless be discontinued or an intervention modified if an unexpected safety concern or other circumstance arises that, in the judgment of the investigators and relevant institutional/ethical oversight body, warrants discontinuation.

Statistical significance and reporting

All statistical tests will be two-sided, with α = 0.05 used for the primary outcome. Continuous variables will be summarized using means and standard deviations when approximately normally distributed and medians and interquartile ranges when distributions are substantially skewed. Categorical variables will be summarized using frequencies and percentages.

For the primary and secondary continuous outcomes, the estimated treatment effect, 95% confidence interval, and P value will be reported. For categorical outcomes, effect estimates such as risk differences, risk ratios, or odds ratios with corresponding 95% confidence intervals will be reported where appropriate.

Statistical analyses will be performed using a validated statistical software IBM SPSS Statistics for Windows, version 29.0 (IBM Corp., Armonk, NY, USA).

Trial status

The current protocol version is Version 1.0. Data collection, including the 3-month follow-up assessments, is expected to be completed by October 2026, followed by data analysis and dissemination of the study findings.

Trial registration

This clinical trial was prospectively registered with ClinicalTrials.gov under registration number NCT07566936 on 26 April 2026. The trial will be conducted in accordance with the principles of the Declaration of Helsinki and applicable national and institutional ethical requirements.

Data management

Study data will be recorded using standardized case report forms and entered into a password-protected electronic database. Data will be checked periodically for completeness, consistency, range errors, missing values, and implausible values. Any discrepancies will be cross-verified against the original source documents and corrected by authorized study personnel. Data corrections will be documented to maintain an appropriate audit trail. Outcome assessments will be performed using standardized procedures and calibrated instruments to promote consistency and reliability throughout the study. The analytical dataset will use unique study identification numbers, and allocation information will not be made available to the blinded outcome assessor.

Data retention

All study records and research data will be stored securely for a minimum of five years after completion of the study, or for the period required by applicable institutional, ethical, or regulatory requirements, whichever is longer.

Auditing

No independent external audit of the trial is planned. Trial conduct, protocol adherence, data completeness, and documentation will be reviewed by the principal investigator and the research team throughout the study. Any important protocol deviations will be documented and reported in accordance with institutional and ethical requirements.

Confidentiality and data protection

Each participant is assigned a unique study identification number. Identifying information is stored separately from the research data to maintain participant confidentiality. Electronic study data are stored on password-protected systems, with access restricted to authorized research personnel. Data handling, storage, and access procedures are conducted in accordance with institutional data-protection policies.

Risk–benefit assessment

Both interventions involve fabrication and use of stabilization splints that are routinely used in prosthodontic and TMD management and are therefore anticipated to involve no more than minimal additional research-related risk. Potential risks associated with splint use may include transient discomfort, mucosal irritation, altered occlusal contacts, or temporary changes in TMD symptoms. Participants will be monitored throughout the study for adverse events and clinically significant treatment-related problems. Any adverse event will be documented and managed according to institutional clinical protocols. Participants requiring additional clinical management will receive appropriate treatment or referral as clinically indicated.

Data access

Access to the identifiable study records will be restricted to authorized members of the research team responsible for the conduct of the trial. The principal investigator will have access to the complete study dataset and will be responsible for its integrity and security. Investigators involved in statistical analysis will receive the coded analysis dataset. Identifying information will not be included in datasets used for analysis or publication. Access to the final dataset by external investigators may be considered following reasonable request to the principal investigator and subject to institutional, ethical, and data-confidentiality requirements.

Protocol amendments

Any substantive modification to the study protocol, including changes to the study objectives, eligibility criteria, intervention procedures, outcomes, sample size, or statistical analysis plan, will be documented through a revised protocol version with the corresponding date. Amendments requiring ethical approval will be submitted to the Institutional Review Board before implementation, except where an immediate modification is necessary to eliminate an apparent hazard to participants; such changes will be documented and reported to the IRB as required. Applicable amendments will also be updated in the clinical trial registry. All substantive protocol deviations and amendments will be reported transparently in subsequent publications.

Post-trial care

Participants will receive appropriate clinical advice regarding continued management of their temporomandibular joint symptoms following completion of the 3-month study follow-up. Participants who experience a clinically relevant problem related to the stabilization splint during the study will receive appropriate clinical assessment and management. Any necessary adjustment, repair, or replacement of a study splint during the trial will be managed according to the predefined intervention protocol. Participants requiring further treatment after completion of the study will be referred for appropriate routine clinical care according to their clinical needs.

Dissemination of results

The results of the trial will be submitted for publication in a peer-reviewed scientific journal irrespective of whether the findings demonstrate a statistically significant difference between the intervention groups. Results may also be disseminated through scientific conferences and academic presentations. No individual participant will be identifiable in any publication or presentation.

Discussion

This randomized controlled trial has been designed to compare digitally fabricated and conventionally fabricated maxillary stabilization splints for the management of TMD within a standardized clinical setting. Although both fabrication approaches are increasingly used in clinical practice, direct comparative clinical evidence remains limited and heterogeneous with respect to fabrication workflows, outcome measures, and follow-up periods. Addressing this evidence gap is relevant as digital workflows become increasingly integrated into prosthodontic care.

Evidence from in vitro studies [15,16] and clinical trials [4,5,12,13,14,17,18,19] suggests that digital fabrication may offer potential advantages in reproducibility, standardization of design, and workflow efficiency. However, these technical and procedural advantages do not necessarily translate into superior clinical outcomes for patients with TMD. The present trial therefore focuses on patient-centered clinical outcomes rather than solely on laboratory or technical measures. The primary outcome is the change in Characteristic Pain Intensity (CPI) from baseline to 3 months, with secondary outcomes including pain-related disability, maximum unassisted mouth opening, jaw functional limitation, temporomandibular joint clicking, oral health-related quality of life, and compliance.

Several features of the study design are intended to strengthen internal validity. Random allocation is used to reduce selection bias, while blinded outcome assessment is intended to minimize outcome-assessment bias. Because the digital and conventional fabrication procedures are inherently distinguishable, participants and operators cannot be completely blinded to the assigned fabrication method; therefore, the study uses an assessor-blinded design. Standardization of splint design, coverage, thickness, and occlusal characteristics is intended to minimize variation attributable to factors other than fabrication technique. The use of validated clinical outcome measures further supports the reliability and interpretability of the findings. In addition, the planned linear mixed-effects models are appropriate for analyzing repeated measurements over time while accounting for within-participant correlation and allowing estimation of the group-by-time treatment effect.

The study also has several limitations. First, its single-center design may limit the generalizability of the findings to other clinical settings, operators, and patient populations. Future multicenter studies involving diverse clinical settings would be valuable for assessing the external validity of the findings. Second, the 3-month follow-up permits assessment of short-term clinical effectiveness but does not provide information regarding the durability of treatment effects or longer-term consequences of splint use. Third, compliance will be assessed using a participant-maintained wear diary and is therefore subject to recall and reporting bias. Objective monitoring of splint wear time was not incorporated into the present protocol. Finally, although standardized fabrication and clinical adjustment procedures are used, some operator- and laboratory-related variability may remain unavoidable in clinical practice.

Overall, this trial is intended to provide clinically relevant evidence regarding whether digitally fabricated stabilization splints produce outcomes comparable to or different from conventionally fabricated splints in patients with TMD. The findings may help determine whether the potential advantages of digital fabrication extend beyond manufacturing and workflow considerations to meaningful patient-centered clinical outcomes.

Data availability

The datasets generated and/or analyzed during the study will be available from the corresponding author upon reasonable request, subject to institutional policies, ethical restrictions, and protection of participant confidentiality.

References

  1. Al Sahman L, AlBagieh H, AlSahman R. Oral health-related quality of life in temporomandibular disorder patients and healthy subjects -a systematic review and meta -analysis. Diagnostics. 2024;14:2183 https://doi.org/10.3390/diagnostics14192183.

    Article  Google Scholar 

  2. Zhang Y, Zhang H, Liu R, Jin S, Huo T, Wei H, et al. The efficacy of treatments for temporomandibular disorders with occlusal splints versus other conservative therapies: a meta -analysis of randomized controlled trials. Oral Surg Oral Med Oral Pathol Oral Radiol. 2025;139:509–20.

    Article  PubMed  Google Scholar 

  3. Gupta AK, Singh RK, Narula V. Centric stabilization occlusal splints versus other conservative therapies in the management of temporomandibular disorders: a systematic review and meta -analysis. Saudi Dent J. 2025;37:52.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Berntsen C, Kleven M, Heian M, Hjortsjö C. Clinical comparison of conventional and additive manufactured stabilization splints. Acta Biomater Odontol Scand. 2018;4:81–9.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Somogyi A, Végh D, Róth I, Hegedüs T, Schmidt P, Hermann P, et al. Therapy for temporomandibular disorders: 3D -printed splints from planning to evaluation. Dent J. 2023;11:126.

    Article  Google Scholar 

  6. Chisini LA, Pires ALC, Poletto-Neto V, Damian MF, Luz MS, Loomans B, et al. Occlusal splint or botulinum toxin-a for jaw muscle pain treatment in probable sleep bruxism: a randomized controlled trial. J Dent. 2024;151:105439.

    Article  CAS  PubMed  Google Scholar 

  7. Almansour FW, Alshammari K, Mohammed Alhajri D, Bader Alzamanan M, Hamed Alduaij F, Walled Abdullah K, et al. Digital versus conventional splints in patients with temporomandibular disorders: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2026;18:e105977.

    PubMed  PubMed Central  Google Scholar 

  8. Hietaharju M, Näpänkangas R, Sipilä K, Teerijoki-Oksa T, Tanner J, Kemppainen P, et al. Importance of the graded chronic pain scale as a biopsychosocial screening instrument in TMD pain patient subtyping. J Oral Facial Pain Headache. 2021;35:303–16.

    Article  PubMed  Google Scholar 

  9. Nabors L, Toledano-Toledano F, Workman B. Graded Chronic Pain Scale (GCPS). In: Medvedev ON, Krägeloh CU, Siegert RJ, Singh NN, editors. Handbook of Assessment in Mindfulness Research. Cham: Springer; 2025.

  10. Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al. International RDC/TMD Consortium Network, International association for Dental Research; Orofacial Pain Special Interest Group, International Association for the Study of Pain. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. J Oral Facial Pain Headache. 2014;28:6–27.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ohrbach R, Larsson P, List T. The jaw functional limitation scale: development, reliability, and validity of 8-item and 20-item versions. J Orofac Pain. 2008;22:219–30.

    PubMed  Google Scholar 

  12. Kokkola O, Suominen AL, Qvintus V. Efficacy of stabilization splint treatment on the oral health-related quality of life-a randomized controlled one- year follow-up trial. J Oral Rehabil. 2018;45:355–62.

    Article  CAS  PubMed  Google Scholar 

  13. Loan HK, Hai HV, Tung NA, Phu NM, Duc NM. Treatment outcomes of temporomandibular disorders using stabilization splint supported by the T-scan system. Eur J Dent. 2026;20:802–7.

    Article  PubMed  Google Scholar 

  14. Kelemen K, König J, Czumbel M, Szabó B, Hegyi P, Gerber G, et al. Additional splint therapy has no superiority in myogenic temporomandibular disorders: a systematic review and meta -analysis of randomized controlled trials. J Prosthodont Res. 2024;68:12–19.

    Article  PubMed  Google Scholar 

  15. Revilla-León M, Cascos-Sánchez R, Zeitler JM, Barmak AB, Kois JC, Gómez-Polo M. Influence of print orientation and wet-dry storage time on the intaglio accuracy of additively manufactured occlusal devices. J Prosthet Dent. 2024;131:1226–34. https://doi.org/10.1016/j.prosdent.2022.12.005

    Article  PubMed  Google Scholar 

  16. Orgev A, Donmez MB, Almogbel L, Cakmak G, Marques VR, Kahveci C, et al. Cameo and intaglio surface stability and variability of additively, subtractively, and conventionally manufactured occlusal devices after long-term storage. J Prosthet Dent. 2024;132:604.e1–604.e7.

    Article  CAS  PubMed  Google Scholar 

  17. Alajbeg IZ, Vrbanović E, Lapić I, Alajbeg I, Vuletić L. Effect of occlusal splint on oxidative stress markers and psychological aspects of chronic temporomandibular pain: a randomized controlled trial. Sci Rep. 2020;10:10981.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Dinsdale A, Atkins C, Golds L, Gough A, Jessen K, Forbes R. The effectiveness of conservative interventions on temporomandibular disorder -related kinesiophobia and pain catastrophizing: a systematic review. Musculoskelet Sci Pract. 2025;77:103328.

    Article  PubMed  Google Scholar 

  19. Orzeszek S, Waliszewska -Prosol M, Ettlin D, Seweryn P, Straburzynski M, Martelletti P, et al. Efficiency of occlusal splint therapy on orofacial muscle pain reduction: a systematic review. BMC Oral Health. 2023;23:180.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research was supported by the Shifa Tameer-e-Millat University Research Grant (Grant No. 053-2025). The funding body had no role in the study design, data collection, data analysis, interpretation of data, manuscript preparation, or the decision to submit the manuscript for publication.

Author information

Authors and Affiliations

  1. Shifa College of Dentistry, Shifa Tameer-e-Millat University, Islamabad, Pakistan

    Aysha Sadaf, Nazia Yazdanie & Muhammad Khan Asif

Authors

  1. Aysha Sadaf
  2. Nazia Yazdanie
  3. Muhammad Khan Asif

Contributions

Aysha Sadaf: Conceptualization, study design, methodology, trial registration on ClinicalTrials.gov, investigation, and writing—original draft and revision. Nazia Yazdanie: Supervision, conceptualization, methodology, scientific guidance, and critical review and revision of the manuscript. Muhammad Khan Asif: Co-supervision, methodology, scientific guidance, and critical review and revision of the manuscript.

Corresponding author

Correspondence to Aysha Sadaf.

Ethics declarations

Competing interests

The authors declare no competing interests.

Informed consent

Written informed consent will be obtained from each participant before enrollment in the trial. A trained member of the study team will explain the study objectives, procedures, potential benefits and foreseeable risks, follow-up requirements, confidentiality measures, and the voluntary nature of participation. Participants will have the opportunity to ask questions and will be given sufficient time to consider participation before providing written consent. Participants will be informed that they may withdraw from the study at any time without affecting their routine dental care. No study-specific procedures will be performed before informed consent has been obtained.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sadaf, A., Yazdanie, N. & Asif, M.K. Effectiveness of digitally fabricated versus conventional stabilizing splints in temporomandibular disorders: a randomized controlled trial protocol. BDJ Open 12, 111 (2026). https://doi.org/10.1038/s41405-026-00495-0

Download citation

  • Received: 15 July 2026

  • Revised: 16 September 2026

  • Accepted: 21 September 2026

  • Published: 16 November 2026

  • Version of record: 16 November 2026

  • DOI: https://doi.org/10.1038/s41405-026-00495-0

来源:Nature 健康护理主题 · nature.com